



Flexion Therapeutics, Inc.  
 Investor Relations Department  
 10 Mall Road  
 Suite 301  
 Burlington, MA 01803  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: FLXN**

Last Trade:	23.15
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	-0.58 <span style="color:red">▼</span> (-2.444%)
Day Range	22.99 - 24.30
52-Week Range	15.93 - 32.25
Volume	1,769,152

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Oct 11, 2017*  
[Flexion Therapeutics Announces Pricing of Public Offering of Common Stock](#)
- Oct 10, 2017*  
[Flexion Therapeutics Announces Proposed Public Offering of Common Stock](#)
- Oct 9, 2017*  
[Flexion Therapeutics to Hold Conference Call at 8:00 a.m. ET to Discuss Recent FDA Approval of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\)](#)
- Oct 6, 2017*  
[Flexion Therapeutics Announces FDA Approval of Zilretta™ \(triamcinolone acetonide extended-release injectable suspension\) for Osteoarthritis \(OA\) Knee Pain](#)
- Sep 7, 2017*  
[Flexion Therapeutics to Present Data on Zilretta™ \(FX006\) at PAINWeek 2017](#)

**Financials** [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 10, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*  
[Quarterly Report \(10-Q\)](#)